Myrcludex B
Myrcludex B is an experimental drug for the treatment of hepatitis B and D. The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism.
Online Inquiry
| CAT# | 10-101-139 |
| CAS | 406461-66-3 |
| Synonyms/Alias | Bulevirtide |
| Sequence | One Letter Code: Myristoyl-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG
Three Letter Code: Myristoyl-Gly-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly |
| Application | Myrcludex B is studied for the treatment of HDV. |
| Purity | ≥98% by HPLC |
| Biological Activity | Bulevirtide is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection. Bulevirtide prevents Hepatitis D entry into cells. It is effective in the reduction of Hepatitis D virus (HDV) RNA levels and improvement of liver inflammation in cases of Hepatitis D infection. |
| Length | 47 |
Storage | −20°C |
Shipping Condition | Shipped at room temperature |
Write a review
Ask a question
My Review for Myrcludex B
Required fields are marked with *
×
Ask a Question for Myrcludex B
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
